Focus on Uterine Fibroids: Evolving Options to Optimize Care

The content for this activity is based on the CME Forum Focus on Uterine Fibroids: Evolving Options to Optimize Care that was presented at the 2017 ACOG Annual Clinical and Scientific Meeting in San Diego, California, on May 8, 2017.

Uterine fibroids, the most common benign pelvic tumors, affect nearly 70% of white women and more than 80% of African American women in the United States by the age of 50 years. They cause significant morbidity, as up to 50% of women with fibroids experience symptoms, including heavy menstrual bleeding, dysmenorrhea, and reproductive dysfunction.

The current mainstay of management is surgical: uterine fibroids account for approximately one-third of all hysterectomies annually in the United States. Until recently, medical management options have been of limited value because of moderate efficacy and/or associated adverse effects. Novel therapies in late-stage development, including oral treatments, may offer better long-term medical management options.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with uterine fibroids.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Cite the risk factors for and symptoms of uterine fibroids
  2. Develop a treatment plan for symptomatic uterine fibroids based on benefits and limitations of available therapies
  3. Describe uterine fibroid treatment options in late-stage development
  4. Employ a strong patient-provider collaborative approach designed to engage patients in discussion about uterine fibroid symptoms and treatments

FACULTY

Sukhbir Sony Singh, MD, FRCSC, FACOG (Program Chair)
Associate Professor and Vice-Chair of Gynecology
Department of Obstetrics and Gynecology
The Ottawa Hospital
University of Ottawa
Ottawa, Ontario, Canada

Erica E. Marsh, MD, MSCI, FACOG
Associate Professor and Chief
Division of Reproductive Endocrinology and Infertility
Department of Obstetrics and Gynecology
University of Michigan Health System
University of Michigan
Ann Arbor, Michigan

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter 

Relationship Identified With:
Sukhbir Sony Singh, MD, FRCSC, FACOG (Program Chair) 

Consultant/Advisor: AbbVie Inc, Allergan Inc., Bayer AG

Grant/Research Support: AbbVie Inc, Allergan Inc., Bayer AG

Speakers Bureau: AbbVie Inc, Allergan Inc., Bayer AG

Erica E. Marsh, MD, MSCI, FACOG

Consultant/Advisor: Allergan Inc.

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months. 

Peer Review

This CME activity has been peer-reviewed by the American Journal of Obstetrics & Gynecology.

Financial Support

This activity has been supported by an independent educational grant from Allergan Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians) 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; and Allergan Inc. do not recommend the use of any agent outside of the labeled indications. 

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
08/07/2017
Course expires: 
08/06/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
08/07/2017
Course expires: 
08/06/2018
Please login or register to take this course.